Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitwise Crypto Industry Innovators ETF (BITQ) vs Moderna, Inc. (MRNA) Price & Performance

Bitwise Crypto Industry Innovators ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Bitwise Crypto Industry Innovators ETF vs Moderna, Inc. — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $23.52, while Moderna, Inc. trades at $67.44 (market cap $26.76B). The key difference: Moderna, Inc. is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.

BITQMRNA
Sector
Crypto-linkedHealth
52-Week High
$30.43$81.80
52-Week Low
$16.74$22.36
Market Cap
$26.76B
Enterprise Value
$22.85B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitwise Crypto Industry Innovators ETF

BITQ trades at $23.18, down 3.13% today amid bearish technical signals. The stock faces selling pressure with moving averages indicating a downtrend, though oscillators show neutral conditions. Support levels cluster around $23-24 while resistance sits at $25-26. Recent news highlights investor rotation away from crypto-related ETFs as Bitcoin prices decline, creating headwinds for BITQ's performance.

The outlook remains cautious given the bearish technical setup and sector-specific challenges. Investment opportunity exists for contrarian investors betting on crypto market recovery, but risks include continued ETF outflows and regulatory uncertainty. The stock's performance remains tightly correlated with broader cryptocurrency sentiment rather than standalone fundamentals.

Moderna, Inc.

Moderna (MRNA) trades at $67.01, down 1.85% today, with a bullish technical signal from moving averages. The company continues to post net losses despite beating EPS estimates in recent quarters, with revenue declining from pandemic peaks. Recent news highlights pipeline expansion into oncology and autoimmune diseases, with an FDA decision on its mRNA flu vaccine expected by August 5, 2026.

While Moderna's pipeline diversification offers long-term growth potential, significant risks remain from persistent negative profitability and high valuation multiples. Analyst consensus is cautious with a $49 price target below current levels, suggesting limited near-term upside despite recent positive developments in vaccine approvals and strategic shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitwise Crypto Industry Innovators ETF

BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.

Read more on BITQ

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA